Evofem Biosciences CFO Justin J. File resigns; Albert Altro appointed interim CFO

Evofem Biosciences, Inc.

Justin J. File resigned as CFO effective April 3, 2023, to pursue other opportunities; no disagreement with company.
Albert Altro, with over 30 years of financial experience, appointed interim CFO on March 6, 2023.
Altro compensated at $275-$450/hour via engagement with his firm Traverse LLC; $40,000 retainer paid.
Company issued a press release on March 9, 2023, announcing the changes.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Justin J. File

Chief Financial Officer

EVFM · Evofem Biosciences, Inc.

Effective: 2023-04-03
Successor: Albert Altro
Filed: March 9, 2023, 6:59 PM ET

On March 3, 2023, Justin J. File provided his notice of resignation from his role as Chief Financial Officer of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), to pursue other opportunities.

Appointed (interim)

Albert Altro

Chief Financial Officer

EVFM · Evofem Biosciences, Inc.

Effective: 2023-03-06
Filed: March 9, 2023, 6:59 PM ET

On March 6, 2023, Albert Altro was appointed as the interim Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Justin J. File resigned as Chief Financial Officer at Evofem Biosciences, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On March 3, 2023, Justin J. File provided his notice of resignation from his role as Chief Financial Officer of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), to pursue other opportunities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Albert Altro was appointed as Chief Financial Officer at Evofem Biosciences, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 6, 2023, Albert Altro was appointed as the interim Chief Financial Officer of the Company.

View on SEC.gov

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001618835-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.